MATTERHORN supports the global adoption of perioperative durvalumab plus FLOT as a new standard for patients with localized gastric and gastroesophageal junction adenocarcinoma,” said Yelena Y.

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Immmunotherapy-based treatments demonstrate effectiveness and safety profiles consistent with clinical trials in real-world setting.

Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Welcome to the Lisata Therapeutics Second Quarter 2025 Financial ...

Australians with Parkinson's disease, neuroblastoma, endometrial cancer, cystic fibrosis and melanoma will have access to new and expanded medicines ...

Recent clinical trials like ADRIATIC and IMforte are shaping the future of small cell lung cancer (SCLC) treatment, explained Angel Qin, MD. She also emphasized the growing role of immunotherapy in ...

In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe th ...

Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other ...

In August 2025, Bristol-Myers Squibb announced a study is to evaluate the safety and effectiveness of triplet therapy of ...

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...